Platelet glycoprotein IIb/IIIa inhibitors: Overview and implications for the anesthesiologist

Anesthesia and Analgesia

Volumn 95, Issue 4, 2002, Pages 879-888

  Chun, Rosaleen ^a   Orser, Beverley A ^a   Madan, Mina ^a  

^a FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; PLACEBO; TICLOPIDINE; TIROFIBAN;

ANESTHESIST; ATHEROSCLEROTIC PLAQUE; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG COST; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; VEIN THROMBOSIS;

EID: 0036784839     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200210000-00017     Document Type: Review

References (51)

1. Madan M, Berkowitz SC, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation 1998;98:2629-35.
2. Van De Graaff E, Steinhubl SR. Antiplatelet medications and their indications in preventing and treating coronary thrombosis. Ann Med 2000;32:561-71.
3. Pharand C, Kertland H, Paradiso-Hardy F. Present and future uses of GP IIb/IIIa inhibitors. Manuscript of the Canadian Cardiovascular Pharmacists Network (CCPN); Merck Frosst Canada Ltd. Educational Grant, Montreal, Canada, 2001.
4. Kleiman NS. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am Heart J 1999;138: S263-75.
5. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437-44.
6. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139: S38-45.
7. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/ IIIa receptor blockade. Circulation 1998;97:1680-8.
8. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/ IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial. Lancet 2001; 357:1915-24.
9. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
10. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-44.
11. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
12. The PARAGON Investigators. International, randomized controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable angina. Circulation 1998;97: 2386-95.
13. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338: 1488-97.
14. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
15. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
16. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
17. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
18. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349:1429-35.
19. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II-Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349:1422-8.
20. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stent in with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
21. Chew DP, Moliterno DJ. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol 2000;36:2028-35.
22. Quinn MJ, Lincoff AM, Kereiakes DJ, et al. Long-term mortality benefit of abciximab in percutaneous intervention [abstract]. Circulation 2001;104(Suppl II):387.
23. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-8.
24. Cannon CP, Weintraub WS, Demopoulos LA, et al. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy: Thrombolysis In Myocardial Infarction. Am J Cardiol 1998;82:731-6.
25. Madan M, Blankenship JC, Berkowitz SD. Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. Curr Opin Hematol 1999;6:334-41.
26. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001;104: 539-43.
27. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase-clinical findings through hospital discharge. Circulation 1987;76:142-54.
28. Blankenship JC, Hellkamp AS, Aguirre FV, et al. Vascular access site complications after percutaneous coronary intervention with abciximab in the evaluation of c7E3 for the prevention of ischemic complications (EPIC) trial. Am J Cardiol 1998;81: 36-40.
29. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-90.
30. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization: PROLOG Investigators. Am J Cardiol 1997; 79:286-91.
31. Alvarez JM. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab. J Thorac Cardiovasc Surg 1998;115:472-3.
32. Boehrer JD, Kereiakes DJ, Navetta FI, et al. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol 1994; 74:1166-70.
33. Dyke CM. Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective. Am Heart J 1999;138:S307-16.
34. Gammie JS, Zenati M, Kormos RL, et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998;65:465-9.
35. Levy J, Kelley A. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time [letter]. Circulation 1997;96:3793-4.
36. Lemmer JH, Metzdorff MT, Krause AH, et al. Emergency coronary artery bypass graft surgery in abciximab-treated patients. Ann Thorac Surg 2000;69:90-5.
37. Despoils GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery. Anesthesiology 1999;91: 1122-43.
38. Dinardo JA. Anesthesia for cardiac surgery. Stamford, CT: Appleton & Lange, 1998:311-2.
39. Steinhubl S, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-8.
40. Juergens CP, Yeung AC, Oesterle SN. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol 1997;80:74-5.
41. Dyke CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Ann Thorac Surg 2000;70:866-72.
42. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J 1999;138:S317-26.
43. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-13.
44. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104:870-5.
45. Hillegass WB, Newman AR, Dominic LR. Economic issues in glycoprotein IIb/IIIa receptor therapy. Am Heart J 1999;136: S24-32.
46. Topol E, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial-EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999;354:2019-24.
47. Cohen DJ, Cosgrove RS, Berezin RH, et al. Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting: results from the ESPRIT trial [abstract]. Circulation 2001; 104(Suppl II):386.
48. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000;35:1288-94.
49. Posner KL, Van Norman GA, Chan V. Adverse cardiac outcomes after noncardiac surgery in patients with prior percutaneous transluminal coronary angioplasty. Anesth Analg 1999; 89:553-60.
50. Schweizer J, Kirch W, Koch R, et al. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. Angiology 2000;51:913-23.
51. Waters JH, Anthony DG, Gottlieb A, Sprung J. Bleeding in a patient receiving platelet aggregation inhibitors. Anesth Analg 2001;93:878-82.